CHU Hôtel-Dieu
CHU Hôtel-Dieu is a French entity in Angers (18 employees) whose listed website resolves to Association AG1-23 SOLEIL, a non-profit patient organization founded in May 2009 that supports French families affected by Glutaric Acidemia Type 1 through medical information, advocacy, and annual community gatherings.
- Company typePrivate
- Founded2009
- Headquarters—
- Headcount11–50
- GTM typeB2C
- OfferingServices
What CHU Hôtel-Dieu does
The record labeled "CHU Hôtel-Dieu" lists an Angers, Pays de la Loire (France) entity with 18 employees and a website URL (ag1-23soleil.fr) that resolves to Association AG1-23 SOLEIL, a French non-profit patient organization. The "CHU" designation typically denotes a Centre Hospitalier Universitaire (university hospital center), but no hospital-specific data is present in the source material; all substantive evidence pertains to the patient association. Association AG1-23 SOLEIL was founded in May 2009 by parents of children diagnosed with Glutaric Acidemia Type 1 (AG1), a rare inherited metabolic disorder, to provide support, advice, and information to affected families.
The association operates as an association loi 1901 under French law, governed by an elected board of directors. Olivier Liandier is identified as President as of 2023. Its activities center on (1) maintaining a medical information section on its website covering AG1 definitions, PNDS (Protocole National de Diagnostic et de Soins) guidelines, and related resources; (2) publishing news, annual vœux, and family témoignages (testimonials); (3) organizing annual family gatherings such as the Weekend AG1 2023 held May 17–21, 2023 in Aigrefeuille-sur-Maine (featuring escape games, animal mediation, relaxation workshops, and Snoezelen sessions); and (4) fundraising through events such as Soirées Cabareterelles (2012) and external donations (e.g., €1,000 from Ville de Seebach in 2013). The website is built on WordPress and hosted by STRATO AG in Berlin; social presence is limited to Facebook and Instagram organic channels. No commercial products, pricing, APIs, AI capabilities, or revenue figures are disclosed.
A pivotal external development for the AG1 community — and by extension the association's mission reach — was the Haute Autorité de Santé's February 3, 2020 recommendation for systematic newborn screening for AG1, formalized by the Arrêté du 9 novembre 2022, with universal neonatal screening in France effective January 1, 2023. The association's own strategic posture remains advocacy- and community-focused rather than commercial or technological.
CHU Hôtel-Dieu firmographics
Firmographics- Name
- CHU Hôtel-Dieu
- Legal name
- Association AG1-23 SOLEIL
- Website
- https://ag1-23soleil.fr
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- CHU Hôtel-Dieu is a French entity in Angers (18 employees) whose listed website resolves to Association AG1-23 SOLEIL, a non-profit patient organization founded in May 2009 that supports French families affected by Glutaric Acidemia Type 1 through medical information, advocacy, and annual community gatherings.
- Ownership category
- akta.pro rank
CHU Hôtel-Dieu business model
Business model- GTM type
- B2C
- Offering type
- Services
Marketing channels2 records
CHU Hôtel-Dieu product offering
Product offeringCore offering
Association AG1-23 SOLEIL is a French non-profit patient association (association loi 1901) that provides support, advice, and information to families of children diagnosed with Glutaric Acidemia Type 1 (AG1), a rare genetic metabolic disorder. The organization offers a member community, annual family gatherings, and an informational website containing medical definitions, PNDS (Protocole National de Diagnostic et de Soins) guidelines, and resources on living with AG1.
Differentiator
Problem solved
Functional benefit
Products and services
- Annual family gathering (Weekend AG1)
- Membership and donation program
CHU Hôtel-Dieu technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
CHU Hôtel-Dieu partnerships and signals
Strategic signalRecent moves4 records
Expansion highlights4 records
CHU Hôtel-Dieu competitors and assessment
Company assessmentBroad incumbents
- AFM-Téléthon: Major French patient association for neuromuscular diseases with substantial fundraising and research-funding capability. Comparable as a French association loi 1901 model focused on rare genetic diseases, though at vastly greater scale.
- Orphanet: Reference portal for rare diseases and orphan drugs, originally French-led. Comparable in serving the AG1 / rare disease information ecosystem that AG1-23 SOLEIL's families rely on, though Orphanet is an information infrastructure rather than a patient-driven support association.
- EURORDIS – Rare Diseases Europe: European-level alliance representing rare disease patient organizations. Directly comparable mission of supporting rare disease patients and influencing EU policy, but operating as a broader umbrella rather than a single-disease association.
- NORD (National Organization for Rare Disorders): US-based umbrella patient organization for rare diseases. Comparable mission of supporting patients with rare conditions (including inherited metabolic disorders) and advocating for screening and research policy, but at national-US scale rather than disease-specific.
Direct peers
- Alliance Maladies Rares: French national umbrella collective of rare disease patient associations. Directly comparable as the collective body to which AG1-23 SOLEIL and similar French patient associations belong, sharing the same patient-advocacy mission at the national level.
- Association Française contre les Myopathies (related to AFM-Téléthon network): French rare disease association network active in patient support, research funding, and policy advocacy. Comparable governance structure (association loi 1901) and target community of families affected by severe genetic conditions.
- Vaincre les Maladies Lysosomales: French patient association supporting families affected by lysosomal storage diseases, several of which (like AG1) are inherited metabolic disorders. Comparable structure as a French association loi 1901 providing family support, information, and advocacy for a specific rare disease group.
Regional players
- Feuerstein Stiftung / German GA1 Network: Glutaric Aciduria Type 1 has historically been more prevalent in certain Amish and German-descended communities, and German-speaking patient/clinical networks exist around GA1. Comparable as a disease-specific counterpart for the same condition in a different geography.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
CHU Hôtel-Dieu social profiles
Digital presenceCHU Hôtel-Dieu financial estimates
Financial estimateRevenue estimate
Valuation estimate
CHU Hôtel-Dieu leadership team
Management profileNumber of profiles
CHU Hôtel-Dieu funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CHU Hôtel-Dieu M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CHU Hôtel-Dieu
What does CHU Hôtel-Dieu do?
Association AG1-23 SOLEIL is a French non-profit patient association (association loi 1901) that provides support, advice, and information to families of children diagnosed with Glutaric Acidemia Type 1 (AG1), a rare genetic metabolic disorder. The organization offers a member community, annual family gatherings, and an informational website containing medical definitions, PNDS (Protocole National de Diagnostic et de Soins) guidelines, and resources on living with AG1.
Is CHU Hôtel-Dieu a public or private company?
CHU Hôtel-Dieu is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was CHU Hôtel-Dieu founded?
CHU Hôtel-Dieu was founded in 2009. It employs 11 to 50 people.
Who are CHU Hôtel-Dieu's main competitors?
Broad incumbents on record are AFM-Téléthon, Orphanet, EURORDIS – Rare Diseases Europe and NORD (National Organization for Rare Disorders). Direct peers are Alliance Maladies Rares, Association Française contre les Myopathies (related to AFM-Téléthon network) and Vaincre les Maladies Lysosomales. Feuerstein Stiftung / German GA1 Network is listed as a regional player.
Does CHU Hôtel-Dieu have an API?
No public API is recorded for CHU Hôtel-Dieu.